Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vixtimotamab (AMV564)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Affimed

Drug class:

CD3 agonist, CD33 inhibitor

Related drugs:

‹

CD33/CLL1 dual CAR-NK cell (0)

GTB-3550 TRIKE (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

CD33/CLL1 dual CAR-NK cell (0)

GTB-3550 TRIKE (0)

›

CD33 positive	Leukemia	CD33 positive	Leukemia	AMV564 Sensitive: D – Preclinical AMV564 Sensitive : D	AMV564 Sensitive: D – Preclinical AMV564 Sensitive : D
CD33 positive	Myelodysplastic Syndrome	CD33 positive	Myelodysplastic Syndrome	AMV564 + PD1 inhibitor Sensitive: D – Preclinical AMV564 + PD1 inhibitor Sensitive : D	AMV564 + PD1 inhibitor Sensitive: D – Preclinical AMV564 + PD1 inhibitor Sensitive : D